Afatinib Improves Progression-Free Cancer Survival

Afatinib, a tyrosine kinase inhibitor, significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial presented at the ESMO 2014 Congress in Madrid show. The Lux-Head&Neck 1 trial showed that patients who received treatment with 40 mg/day oral afatinib had a 20% reduction in risk of progression or death compared to patients who received methotrexate, with a median progression-free survival of 2.6 months.  read more

Read the whole article on

More from